Document is current
Any future updates will be listed below
-
Authors
Russo, Mariangela https://orcid.org/0000-0003-4625-1449
Pompei, Simone https://orcid.org/0000-0002-6673-7991
Sogari, Alberto https://orcid.org/0000-0003-0612-6109
Corigliano, Mattia https://orcid.org/0000-0002-6645-6778
Crisafulli, Giovanni https://orcid.org/0000-0002-5511-1555
Puliafito, Alberto
Lamba, Simona
Erriquez, Jessica
Bertotti, Andrea
Gherardi, Marco https://orcid.org/0000-0002-7745-8269
Di Nicolantonio, Federica https://orcid.org/0000-0001-9618-2010
Bardelli, Alberto https://orcid.org/0000-0003-1647-5070
Cosentino Lagomarsino, Marco https://orcid.org/0000-0003-0235-0445
- License Information
-
More Information
Article History
Received: 27 April 2021
Accepted: 25 May 2022
First Online: 11 July 2022
Competing interests
: A. Bardelli reports receiving commercial research grants from Neophore, AstraZeneca and Boehringer; he is an advisory board member/unpaid consultant for Inivata and Neophore, holds ownership interest in Neophore, and is an advisory board member/consultant for Illumina, Guardant Health, Inivata and Roche/Genentech Global CRC. All the other authors declare no competing interests.
